fig2
![EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF<sup>V600E</sup> mutation: a case report and review of literature](https://image.oaes.cc/069de34b-8bbb-463f-9756-7f0b498e6e6a/4425.fig.2.jpg)
Figure 2. The changes in the carcinoembryonic antigen (CEA) level during the patient’s clinical course.
Figure 2. The changes in the carcinoembryonic antigen (CEA) level during the patient’s clinical course.
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/